HC Wainwright Has Bullish Estimate for FULC FY2024 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a report issued on Thursday, November 14th. HC Wainwright analyst A. Fein now expects that the company will post earnings of ($0.12) per share for the year, up from their previous estimate of ($0.15). HC Wainwright has a “Neutral” rating and a $4.00 price target on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ Q4 2024 earnings at ($0.23) EPS, Q1 2025 earnings at ($0.22) EPS, Q2 2025 earnings at ($0.21) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.81) EPS, FY2026 earnings at ($1.00) EPS, FY2027 earnings at ($0.99) EPS and FY2028 earnings at ($0.84) EPS.

FULC has been the subject of several other reports. Leerink Partners reissued a “market perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, September 12th. Stifel Nicolaus cut shares of Fulcrum Therapeutics from a “buy” rating to a “hold” rating and reduced their target price for the company from $22.00 to $3.00 in a research report on Thursday, September 12th. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Thursday. Bank of America downgraded shares of Fulcrum Therapeutics from a “neutral” rating to an “underperform” rating and cut their price objective for the company from $10.00 to $2.00 in a report on Thursday, September 12th. Finally, Cantor Fitzgerald lowered shares of Fulcrum Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Thursday, September 12th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $9.33.

Fulcrum Therapeutics Price Performance

NASDAQ FULC opened at $3.01 on Monday. The stock’s 50 day simple moving average is $3.75 and its 200-day simple moving average is $6.47. The company has a market cap of $162.36 million, a PE ratio of -9.69 and a beta of 2.24. Fulcrum Therapeutics has a 1-year low of $2.87 and a 1-year high of $13.70.

Institutional Trading of Fulcrum Therapeutics

Several hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in Fulcrum Therapeutics in the first quarter valued at approximately $308,000. SG Americas Securities LLC acquired a new stake in shares of Fulcrum Therapeutics during the 1st quarter worth about $115,000. Vanguard Group Inc. lifted its position in Fulcrum Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 2,538,665 shares of the company’s stock valued at $23,965,000 after buying an additional 18,681 shares during the last quarter. StemPoint Capital LP boosted its stake in Fulcrum Therapeutics by 8.1% during the first quarter. StemPoint Capital LP now owns 407,108 shares of the company’s stock worth $3,843,000 after buying an additional 30,535 shares during the period. Finally, Jane Street Group LLC lifted its holdings in shares of Fulcrum Therapeutics by 54.3% in the 1st quarter. Jane Street Group LLC now owns 535,062 shares of the company’s stock worth $5,051,000 after acquiring an additional 188,212 shares during the last quarter. Hedge funds and other institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.